Search for a command to run...
Hypoglycaemia management kits (HMKs) are increasingly recognised as a crucial component of care in mental health hospitals, particularly for patients with diabetes or those on medications that affect glucose metabolism. Emerging evidence suggests that the implementation of HMKs in these settings has significant benefits in both clinical and psychological outcomes. Properly stocked kits, which typically include glucose tablets, glucagon, and syringes, enable quick and effective treatment of hypoglycaemic events, reducing the risk of severe complications such as seizures, coma, or death. Studies show that patients with mental health conditions, especially those taking antipsychotic medications, are at increased risk of developing metabolic disturbances, including hypoglycaemia. HMKs help mitigate these risks, improving patient safety and contributing to better management of comorbid conditions. Additionally, the presence of these kits can alleviate anxiety among patients and staff, enhance confidence in managing medical emergencies, and reduce the burden on healthcare professionals by preventing preventable hospitalizations. While data on long-term outcomes is still limited, current evidence supports the integration of HMKs into standard care protocols within mental health hospitals as a means of improving both physical and mental health outcomes, and promoting a more holistic, patient-centred approach to care. Further research is needed to refine guidelines and assess the cost-effectiveness of HMK use in this population.